Norges Bank
IOVA icon

Norges Bank’s Iovance Biotherapeutics IOVA Stock Holding History

Norges Bank’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-260,148
Closed -$866K – 1738
2025
Q1 		$866K Sell
260,148
-156,089
-38% -$805K ﹤0.01% 1640
2024
Q4 		$3.08M Sell
416,237
-350,808
-46% -$3.25M ﹤0.01% 1621
2024
Q3 		$7.2M Sell
767,045
-175,938
-19% -$1.67M ﹤0.01% 1432
2024
Q2 		$7.56M Sell
942,983
-149,004
-14% -$1.6M ﹤0.01% 1465
2024
Q1 		$16.2M Sell
1,091,987
-28,470
-3% -$331K ﹤0.01% 1319
2023
Q4 		$9.11M Hold
1,120,457
– – ﹤0.01% 1519
2023
Q3 		$5.1M Hold
1,120,457
– – ﹤0.01% 1668
2023
Q2 		$7.89M Sell
1,120,457
-1,319,600
-54% -$9.44M ﹤0.01% 1606
2023
Q1 		$14.9M Sell
2,440,057
-534,800
-18% -$3.69M ﹤0.01% 1412
2022
Q4 		$19M Buy
2,974,857
+1,578,500
+113% +$12.3M ﹤0.01% 1296
2022
Q3 		$13.4M Buy
1,396,357
+42,122
+3% +$486K ﹤0.01% 1418
2022
Q2 		$15M Buy
1,354,235
+496
+0% +$6.5K ﹤0.01% 1383
2022
Q1 		$22.5M Buy
1,353,739
+52,289
+4% +$809K ﹤0.01% 1334
2021
Q4 		$24.8M Buy
1,301,450
+63,252
+5% +$1.39M 0.01% 1357
2021
Q3 		$30.5M Buy
1,238,198
+52,525
+4% +$1.24M 0.01% 1204
2021
Q2 		$30.9M Sell
1,185,673
-38,743
-3% -$1.01M 0.01% 1257
2021
Q1 		$38.8M Sell
1,224,416
-248,215
-17% -$10.3M 0.01% 1121
2020
Q4 		$68.3M Sell
1,472,631
-57,523
-4% -$2.28M 0.02% 771
2020
Q3 		$50.4M Buy
1,530,154
+80,375
+6% +$2.46M 0.01% 834
2020
Q2 		$39.8M Buy
1,449,779
+140,800
+11% +$4.63M 0.01% 984
2020
Q1 		$39.2M Hold
1,308,979
– – 0.01% 824
2019
Q4 		$36.2M Buy
1,308,979
+701,550
+115% +$16M 0.01% 1119
2019
Q3 		$11.1M Buy
607,429
+587,429
+2,937% +$13M ﹤0.01% 1739
2019
Q2 		$490K Hold
20,000
– – ﹤0.01% 2058
2019
Q1 		$190K Hold
20,000
– – ﹤0.01% 2099
2018
Q4 		$177K Buy
+20,000
New +$193K ﹤0.01% 2103

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Norges Bank's IOVA Position: Q2 2025 in Review

Norges Bank sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 260,148 shares — an estimated $866K sold.

Norges Bank first reported a position in IOVA in Q4 2018 and held it in 26 quarters. The position peaked at $68.3M in Q4 2020. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Norges Bank reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Norges Bank sold 260,148 Iovance Biotherapeutics shares in Q2 2025, an estimated $866K.
  • Norges Bank first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 26 quarters.
  • Norges Bank's Iovance Biotherapeutics position peaked at $68.3M in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Norges Bank's 13F filing for Q2 2025, filed 13 Aug 2025.